Scarica l'app Stockscreener
8.48
5.60%
0.45
Dopo l'orario di chiusura:
8.48
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NVAX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$8.03
Aprire:
$8.02
Volume 24 ore:
6.08M
Relative Volume:
0.73
Capitalizzazione di mercato:
$1.38B
Reddito:
$847.25M
Utile/perdita netta:
$-284.86M
Rapporto P/E:
-3.7031
EPS:
-2.29
Flusso di cassa netto:
$-112.35M
1 W Prestazione:
+26.00%
1M Prestazione:
+23.98%
6M Prestazione:
+8.30%
1 anno Prestazione:
-28.44%
Intervallo 1D:
$8.02
$8.505
Intervallo di 1 settimana:
$7.18
$9.1278
Portata 52W:
$5.01
$15.22
Novavax Inc Stock (NVAX) Company Profile
Nome
Novavax Inc
Settore
Industria
Telefono
240-268-2000
Indirizzo
700 QUINCE ORCHARD ROAD, GAITHERSBURG, MD
Confronta NVAX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
8.48 | 1.30B | 847.25M | -284.86M | -112.35M | -2.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Novavax Inc Stock (NVAX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-17 | Iniziato | Citigroup | Sell |
| 2025-02-28 | Iniziato | BTIG Research | Buy |
| 2024-07-30 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-05-10 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2024-05-10 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2023-08-09 | Aggiornamento | B. Riley Securities | Neutral → Buy |
| 2023-04-20 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-03-01 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2023-01-09 | Reiterato | B. Riley Securities | Buy |
| 2022-12-30 | Reiterato | H.C. Wainwright | Buy |
| 2022-12-02 | Iniziato | Jefferies | Hold |
| 2022-09-22 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-05-20 | Iniziato | BofA Securities | Underperform |
| 2022-02-23 | Reiterato | B. Riley Securities | Buy |
| 2022-02-22 | Ripresa | Jefferies | Buy |
| 2022-01-21 | Iniziato | Cowen | Outperform |
| 2021-05-12 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-12-14 | Iniziato | Jefferies | Buy |
| 2020-08-06 | Reiterato | H.C. Wainwright | Buy |
| 2020-08-05 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-08-05 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
| 2020-07-16 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-08 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2020-06-29 | Reiterato | B. Riley FBR | Buy |
| 2020-06-29 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-05 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2020-05-28 | Reiterato | B. Riley FBR | Buy |
| 2020-05-12 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-30 | Reiterato | H.C. Wainwright | Buy |
| 2019-11-27 | Ripresa | B. Riley FBR | Buy |
| 2019-08-14 | Reiterato | H.C. Wainwright | Buy |
| 2019-02-28 | Downgrade | Piper Jaffray | Overweight → Underweight |
| 2018-12-18 | Iniziato | Ladenburg Thalmann | Buy |
| 2018-12-11 | Iniziato | Oppenheimer | Outperform |
| 2018-11-26 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2018-09-21 | Aggiornamento | JP Morgan | Underweight → Overweight |
| 2018-03-29 | Aggiornamento | Seaport Global Securities | Neutral → Buy |
Mostra tutto
Novavax Inc Borsa (NVAX) Ultime notizie
CDC Shooting Linked To Suspect's COVID-19 Vaccine Beliefs, Former Staff Blame RFK Jr. Hostility Toward Agency - Benzinga
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick - Yahoo Finance
Vinay Prasad's Comeback To FDA Sparks Debate Over Regulatory Direction - Benzinga
Biotech sector slips amid reported return of ousted FDA official (SRPT:NASDAQ) - Seeking Alpha
Former Surgeon General Slams RFK Jr. Over mRNA Cuts, Says US 'Conceding To China,' 2 Million Lives At Risk - Benzinga
NVAX Stock Gains on Q2 Earnings & Sales Beat, Ups '25 Sales View - MSN
Novavax Stock Surges 24% Amid Milestone Payment and Strategic Gains - AInvest
Novavax slips as Citi launches with Sell rating on pipeline concerns - MSN
Novavax’s Q2 Financial Success: A Game Changer? - StocksToTrade
Novavax, Inc. (NASDAQ:NVAX) Q2 2025 Earnings Call Transcript - Insider Monkey
Novavax Reports Strong Earnings Amid Strategic Shifts - TipRanks
Decoding Novavax Inc (NVAX): A Strategic SWOT Insight - GuruFocus
Novavax: Q2 Earnings Snapshot - Connecticut Post
Novavax Q2 2025 Earnings Call Transcript - MarketBeat
Novavax (NVAX) Profit Jumps on Milestone - The Globe and Mail
Novavax raises 2025 revenue target to $1.05B with milestone payments and streamlined expenses as Sanofi partnership progresses - MSN
Novavax higher after Q2 beat as partnerships brighten outlook - MSN
Novavax (NVAX) Reports Q2 Progress and Key Partnership Developme - GuruFocus
Transcript : Novavax, Inc., Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener
Novavax expects post-marketing Covid study to cost up to $90M - Endpoints News
Novavax stock surges as HHS pulls mRNA vaccine funding, opening doors for alternative technologies - The Business Journals
Novavax outlook 2025 adjusted revenue $1 bln to $1.05 bln versus IBES estimate $1.02 bln - MarketScreener
Novavax CFO Says Sanofi To Cover Majority Of Future Nuvaxovid Study Costs, Retail Urges Partnership Diversification - Investing.com India
Novavax banks on vaccine supply partnerships to boost 2025 revenue - Reuters
Novavax Shares Rise Following Avian Flu Vaccine Success - StocksToTrade
Novavax’s Vaccine Breakthrough Signals Optimism Amid Changing Market Dynamics - timothysykes.com
Novavax Ups Outlook, Eyes Stronger Nuvaxovid Sales - Yahoo Finance
Novavax (NVAX) Boosts 2025 Revenue Outlook Amid Strategic Collab - GuruFocus
Earnings call transcript: Novavax Q2 2025 reports unexpected profit, stock surges - Investing.com Canada
Novavax Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Can Novavax’s Innovation Fuel a Stock Rebound? - StocksToTrade
Novavax Q2 2025 slides: Milestone revenue drives profit amid strategic shift - Investing.com Australia
Novavax Q2 Earnings, Revenue Fall; Full-Year Adjusted Revenue Outlook Raised - MarketScreener
Novavax (NVAX) Raises Revenue Forecast Amid Strong Vaccine Partn - GuruFocus
Novavax (NVAX) Q2 Earnings and Revenues Top Estimates - Yahoo Finance
Novavax (NVAX) Surpasses Earnings Expectations with Revenue Boos - GuruFocus
Earnings snapshot: Novavax tops Q2 estimates; raises full-year outlook - MSN
Novavax stock higher on Q2 beat, guidance (NVAX:NASDAQ) - Seeking Alpha
Novavax raises annual revenue forecast on vaccine supply partnerships - Reuters
Novavax lifts 2025 revenue outlook after FDA milestone payment By Investing.com - Investing.com Canada
Novavax earnings beat by $0.68, revenue topped estimates - Investing.com Canada
Novavax Inc (NVAX) Q2 2025 Earnings: EPS of $0.62 Beats Estimate, Revenue Surges to $239 Million - GuruFocus
Novavax Reports Second Quarter 2025 Financial Results and Operat - GuruFocus
Novavax's Strategic Transformation and Revenue Catalysts in 2025: A High-Conviction Play in Vaccine Innovation - AInvest
Novavax beats quarterly revenue estimates on milestone payment - Yahoo Finance
Earnings Flash (NVAX) Novavax, Inc. Reports Q2 Revenue $239.2M, vs. FactSet Est of $152.6M - MarketScreener
Novavax Reports Second Quarter 2025 Financial Results and Operational Highlights - TradingView
Earnings Flash (NVAX) Novavax Posts Q2 Revenue $239.2M, vs. FactSet Est of $152.6M - MarketScreener
NOVAVAX INC SEC 10-Q Report - TradingView
RFK Jr. Halts $500 Million In mRNA Vaccine Projects Backed By Pfizer, Moderna: 'We're Prioritizing Safer, Broader Strategies' - Benzinga
Novavax Inc Azioni (NVAX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.91%
3.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):